全文获取类型
收费全文 | 20600篇 |
免费 | 1461篇 |
国内免费 | 97篇 |
专业分类
耳鼻咽喉 | 201篇 |
儿科学 | 393篇 |
妇产科学 | 471篇 |
基础医学 | 2864篇 |
口腔科学 | 247篇 |
临床医学 | 1866篇 |
内科学 | 4848篇 |
皮肤病学 | 424篇 |
神经病学 | 2021篇 |
特种医学 | 962篇 |
外国民族医学 | 5篇 |
外科学 | 3434篇 |
综合类 | 88篇 |
一般理论 | 7篇 |
预防医学 | 1149篇 |
眼科学 | 188篇 |
药学 | 1329篇 |
中国医学 | 23篇 |
肿瘤学 | 1638篇 |
出版年
2023年 | 116篇 |
2022年 | 141篇 |
2021年 | 540篇 |
2020年 | 257篇 |
2019年 | 520篇 |
2018年 | 615篇 |
2017年 | 419篇 |
2016年 | 426篇 |
2015年 | 509篇 |
2014年 | 799篇 |
2013年 | 957篇 |
2012年 | 1520篇 |
2011年 | 1580篇 |
2010年 | 859篇 |
2009年 | 838篇 |
2008年 | 1315篇 |
2007年 | 1265篇 |
2006年 | 1240篇 |
2005年 | 1134篇 |
2004年 | 1101篇 |
2003年 | 942篇 |
2002年 | 895篇 |
2001年 | 340篇 |
2000年 | 315篇 |
1999年 | 284篇 |
1998年 | 227篇 |
1997年 | 195篇 |
1996年 | 151篇 |
1995年 | 128篇 |
1994年 | 132篇 |
1993年 | 94篇 |
1992年 | 199篇 |
1991年 | 150篇 |
1990年 | 155篇 |
1989年 | 160篇 |
1988年 | 159篇 |
1987年 | 150篇 |
1986年 | 113篇 |
1985年 | 116篇 |
1984年 | 95篇 |
1983年 | 80篇 |
1979年 | 61篇 |
1978年 | 53篇 |
1974年 | 64篇 |
1973年 | 56篇 |
1972年 | 55篇 |
1971年 | 60篇 |
1970年 | 53篇 |
1969年 | 52篇 |
1967年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Ragnhild B. Wijma Marloes Emous Merel van den Broek Anke Laskewitz Anneke C. Muller Kobold André P. van Beek 《Surgery for obesity and related diseases》2019,15(1):73-81
Background
Early dumping is a poorly defined and incompletely understood complication after Roux-en-Y gastric (RYGB).Objective
We performed a mixed-meal tolerance test in patients after RYGB to address the prevalence of early dumping and to gain further insight into its pathophysiology.Setting
The study was conducted in a regional hospital in the northern part of the Netherlands.Methods
From a random sample of patients who underwent primary RYGB between 2008 and 2011, 46 patients completed the mixed-meal tolerance test. The dumping severity score for early dumping was assessed every 30 minutes. A sum score at 30 or 60 minutes of ≥5 and an incremental score of ≥3 points were defined as indicating a high suspicion of early dumping. Blood samples were collected at baseline, every 10 minutes during the first half hour, and at 60 minutes after the start.Results
The prevalence of a high suspicion of early dumping was 26%. No differences were seen for absolute hematocrit value, inactive glucagon-like peptide-1, and vasoactive intestinal peptide between patients with or without early dumping. Patients at high suspicion of early dumping had higher levels of active glucagon-like peptide-1 and peptide YY.Conclusion
The prevalence of complaints at high suspicion of early dumping in a random population of patients after RYGB is 26% in response to a mixed-meal tolerance test. Postprandial increases in both glucagon-like peptide-1 and peptide YY are associated with symptoms of early dumping, suggesting gut L-cell overactivity in this syndrome. 相似文献6.
7.
8.
9.
Harinakshi Sanikini David C. Muller Marisa Sophiea Sabina Rinaldi Antonio Agudo Eric J. Duell Elisabete Weiderpass Kim Overvad Anne Tjønneland Jytte Halkjær Marie-Christine Boutron-Ruault Franck Carbonnel Iris Cervenka Heiner Boeing Rudolf Kaaks Tilman Kühn Antonia Trichopoulou Georgia Martimianaki Anna Karakatsani Valeria Pala Domenico Palli Amalia Mattiello Rosario Tumino Carlotta Sacerdote Guri Skeie Charlotta Rylander María-Dolores Chirlaque López Maria-Jose Sánchez Eva Ardanaz Sara Regnér Tanja Stocks Bas Bueno-de-Mesquita Roel C.H. Vermeulen Dagfinn Aune Tammy Y.N. Tong Nathalie Kliemann Neil Murphy Marc Chadeau-Hyam Marc J. Gunter Amanda J. Cross 《International journal of cancer. Journal international du cancer》2020,146(4):929-942
Obesity has been associated with upper gastrointestinal cancers; however, there are limited prospective data on associations by subtype/subsite. Obesity can impact hormonal factors, which have been hypothesized to play a role in these cancers. We investigated anthropometric and reproductive factors in relation to esophageal and gastric cancer by subtype and subsite for 476,160 participants from the European Prospective Investigation into Cancer and Nutrition cohort. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox models. During a mean follow-up of 14 years, 220 esophageal adenocarcinomas (EA), 195 esophageal squamous cell carcinomas, 243 gastric cardia (GC) and 373 gastric noncardia (GNC) cancers were diagnosed. Body mass index (BMI) was associated with EA in men (BMI ≥30 vs. 18.5–25 kg/m2: HR = 1.94, 95% CI: 1.25–3.03) and women (HR = 2.66, 95% CI: 1.15–6.19); however, adjustment for waist-to-hip ratio (WHR) attenuated these associations. After mutual adjustment for BMI and HC, respectively, WHR and waist circumference (WC) were associated with EA in men (HR = 3.47, 95% CI: 1.99–6.06 for WHR >0.96 vs. <0.91; HR = 2.67, 95% CI: 1.52–4.72 for WC >98 vs. <90 cm) and women (HR = 4.40, 95% CI: 1.35–14.33 for WHR >0.82 vs. <0.76; HR = 5.67, 95% CI: 1.76–18.26 for WC >84 vs. <74 cm). WHR was also positively associated with GC in women, and WC was positively associated with GC in men. Inverse associations were observed between parity and EA (HR = 0.38, 95% CI: 0.14–0.99; >2 vs. 0) and age at first pregnancy and GNC (HR = 0.54, 95% CI: 0.32–0.91; >26 vs. <22 years); whereas bilateral ovariectomy was positively associated with GNC (HR = 1.87, 95% CI: 1.04–3.36). These findings support a role for hormonal pathways in upper gastrointestinal cancers. 相似文献
10.
Thierry Patrice David Olivier Ludovic Bourre 《Journal of environmental pathology, toxicology and oncology》2006,25(1-2):467-485
Photodynamic therapy (PDT) is based on the selective light activation of an exogenously given drug to patients. PDT acts mainly on cell membranes either of neovascular endothelial cells or of cancer cells leading to cancer cell death. Six drugs are now marketed based on clinical assays in various indications, which showed a clear cost efficiency as compared to other classical procedures. PDT is easy to handle and can be performed in medical installations fitting the conditions of health care in developing countries. Its cost effectiveness could represent an appropriate solution to the increasing number of cancers of various origin. However despite all the clinical results now available, PDT development remains slow. The reasons for this situation include cost of development, intellectual property, and competition between pharmaceutical companies. 相似文献